GeneGo Renews Its Agreement With Bayer Schering Pharma AG for Another Three Years
"Bayer Schering Pharma was one of our first customers and we appreciatetheir loyalty," said Julie Bryant, Vice President of Business Development atGeneGo. "MetaCore is widely used in Bayer in multiple departments includingbioinformatics, oncology, cardiology and women's health for data mining andanalysis of multiple omics experimental data such as gene expression andproteomics."
About GeneGo, Inc.
GeneGo, Inc. develops systems biology technology such as compound basedpathway analysis, cheminformatics & bioinformatics software for life scienceresearch. The original computational MetaDiscovery(TM) platform allows anintegration and expert analysis of different kinds of experimental data (mRNAexpression, proteomics, metabolomics, microRNA assays and other phenotypicdata) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics)within the framework of curated biological pathways and networks. GeneGo'sflagship product, MetaCore 5.1(TM), assists pharmaceutical scientists in theareas of target selection and validation, data mining in biology,identification of biomarkers for disease states and toxicology. The secondproduct, MetaDrug 5.1(TM) is designed for prediction of human metabolism,toxicity and biological effects for novel small molecules compounds.MetaBase(TM) represents the knowledge base for MetaCore.
For more information, please visit the company's web site athttp://www.genego.com.
SOURCE GeneGo, Inc.
You May Also Like